

Daiichi Sankyo Introduction

History: Daiichi Sankyo Company is a Japanese pharmaceutical company, with a global distribution network. It draws upon over 120 years of experience in scientific innovation and is committed to using this experience to continue to help patients. Today's Daiichi Sankyo was founded through the merger of Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited, two century-old Japanese pharmaceutical companies. The headquarters remain in Japan (Tokyo), with other major offices in the United States (New Jersey), and Germany (Munich). Daiichi Sankyo has 16.000+ employees worldwide, and well over 2.000 in Europe.

Footprint: Through Daiichi Sankyo Europe GmbH (DSE) in Munich, the company has a solid presence in the European Union. The manufacturing facility in Pfaffhofen, Germany, is of strategic importance and contributes significantly to DSE's overall global production capacity. Indeed, the Pfaffhofen facility is its largest outside of Japan. In addition to its German footprint, DSE has affiliates in 13 European countries, working across Europe to continuously improve patient's lives and lead in innovation. DSE is a competitive player, its pioneering approach and scientific expertise improved the lives of patients in Europe and worldwide. Daiichi Sankyo has formed an alliance with AstraZeneca, with the goal of bringing novel Oncology



treatments to more oncologists and patients. This alliance enhances Daiichi Sankyo's already significant European footprint, allowing for enhanced delivery of new and life-changing cancer treatments.

Portfolio & Pipeline: As a research-based company, Daiichi Sankyo is primarily focused on providing novel therapies in oncology and cardiovascular disease. **Art.4(2) first indent**

Its current portfolio of innovative and generic products mirrors Daiichi Sankyo's focus on fulfilling patients' unmet therapeutic needs. With a robust development pipeline and candidate therapies across all phases of clinical development, Daiichi Sankyo's current trajectory is likely to become a worldwide leader for the treatment of cancer and development of oncologic medicines.

Engagement: As a Japanese company on a growth trajectory and considering its significant European presence, legislative developments in the Union are of absolute interest for DSE. Currently, the main source of concern is represented by the upcoming revision of the General Pharmaceutical Legislation. Even though Daiichi Sankyo is a Japanese company, Europe remains a key focus area. Daiichi Sankyo wants the European Union's pharmaceutical framework to remain reliable and innovation-focused, resulting in the EU remaining an attractive market for continued investments.

Outlook: Daiichi Sankyo's active engagement and growth trajectory strengthen its global position. It is crucial for Daiichi to build up a dialogue with EU institutional stakeholders, as Europe is a key partner for Daiichi Sankyo's growth and an important market for investment.

Talking Points

- **Framework for research in oncology in the EU:** Oncology R&D is a key priority, and Daiichi Sankyo invests over ^{Art. 4(2)(a)} of its yearly global revenue. Between 2021 and 2026, this is expected to result in a total of over ^{Art. 4(2) first indent} of total investment. How can the EU and Japan work even closer together to maintain or expand the level of cooperation?
- **Trade Alliance Japan/EU/US:** The EU – Japan economic partnership agreement entered into force on February 1, 2019. Japan and the United States have a free trade agreement as well. These agreements reduce trade barriers between, allowing for these major global economies to increase their economic competitiveness. Strategic economic partnerships are important in a globally volatile situation. How can the EU and Japan work even closer together to maintain or expand the level of cooperation?